C2i Genomics
C2i Genomics is a New York-based company that employs a whole-genome intelligence platform to enhance cancer treatment and monitoring, offering a blood test that detects residual cancer and utilizes a SaaS solution for global monitoring.
Company Overview
C2i Genomics operates a state-of-the-art whole-genome cancer treatment intelligence platform. It focuses on providing advanced solutions for cancer detection, monitoring, and treatment progression. The company's mission is to enhance how cancer is monitored and treated by offering innovative tools that integrate with existing genomic technologies.
Services
C2i Genomics offers a range of services centered around their whole-genome cancer treatment intelligence platform. This includes a blood test designed to detect minimal residual disease, allowing for effective monitoring of cancer treatment, progression, and recurrence. Additionally, they have developed a Software as a Service (SaaS) solution that provides global tumor burden monitoring through their platform. This enables real-time cancer detection and monitoring, which is integrated with genome sequencers globally.
Technology Platform
The technology platform of C2i Genomics is cloud-based, providing real-time data and insights into cancer detection and monitoring. By integrating with thousands of genome sequencers worldwide, the platform allows for accessible and comprehensive cancer monitoring. Since its inception, the platform has successfully processed over 1,000 samples, demonstrating its capability and efficiency in real-world applications.
Global Presence
C2i Genomics is headquartered in New York, with a robust R&D center located in Israel, and a sequencing lab situated in Watertown, Massachusetts. This global presence ensures that the company operates on the cutting edge of research and development in the field of genomics and cancer treatment. By leveraging their distinct geographical locations, they can integrate and utilize diverse resources and expertise.
Partnership with Veracyte
C2i Genomics is part of Veracyte, which focuses on enhancing cancer treatment and monitoring. This partnership allows C2i Genomics to leverage Veracyte's expertise and resources, furthering their mission to improve cancer care through advanced genomic solutions.